Curanex Pharmaceuticals Inc (CURX)
| Market Cap | 238.51M |
| Revenue (ttm) | n/a |
| Net Income | -435,034 |
| EPS | -0.02 |
| Shares Out | 27.75M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 545,357 |
| Open | 8.27 |
| Previous Close | 8.19 |
| Day's Range | 8.27 - 8.60 |
| 52-Week Range | 3.61 - 8.60 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 9, 2025 |
About CURX
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. The company was founded in 1996 and is headquartered in Jericho, New York.
Financial Performance
Financial StatementsNews
Curanex Expands Scientific Advisory Board With Two Distinguished Researchers
New Appointments Bring Deep Expertise in Immunology and Infectious Disease to Advance IND Submission and Intellectual Property Strategy
Curanex Appoints Two Veteran Industry Leaders to Scientific Advisory Board
New Advisors Bring 50+ Years of Leadership Experience With 2 of the Top 10 Global Pharmaceuticals Companies Jericho, New York, March 11, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq:...
Curanex Forms World Class Scientific Advisory Board
Board Includes Former Fortune 100 Pharma Executive and Leading US Medical Research Academic Jericho, New York, March 05, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex”...
Curanex Provides Operational Update on Key Regulatory Milestones
Company Completes GMP Pilot for Phyto-N, Targets Ulcerative Colitis IND Submission Q4 2026 Jericho, New York, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” o...
Curanex Pharmaceuticals Inc. Engages Strategic Investor Relations to Enhance Investor Communications and Engagement
Jericho, New York, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a developmental-stage pharmaceutical company focused on discovering and d...
Curanex Pharmaceuticals Inc. Announces Exercise of the Over-Allotment Option by Underwriters
Jericho, New York, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a developmental stage pharmaceutical company focused on discovering and ...
U.S. IPO Weekly Recap: Quiet Week As IPO Market Gears Up For A Busy Fall
Four small issuers and two SPACs priced offerings in the past week, and a few names joined the pipeline. The largest deals of the week came from the pair of blank check IPOs. There are no IPOs current...
Curanex Pharmaceuticals Inc. Announces Closing of its Initial Public Offering
Jericho, New York, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) ("Curanex" or the "Company"), a developmental stage pharmaceutical company focused on discovering and d...
Curanex Pharmaceuticals Inc. Announces Pricing of its Initial Public Offering
Jericho, New York, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) ("Curanex" or the "Company"), a developmental stage pharmaceutical company focused on discovering and d...
Preclinical biopharma Curanex Pharmaceuticals files for a $10 million IPO
Curanex Pharmaceuticals, a preclinical biopharma developing botanical-based treatments for various diseases, filed on Wednesday with the SEC to raise up to $10 million in an initial public offering.
Curanex Pharmaceuticals IPO Registration Document (S-1)
Curanex Pharmaceuticals has filed to go public with an IPO on the NASDAQ.